MedTrace Logo

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT02546388 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better.

OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.

Conditions

  • Sarcoidosis

Interventions

DRUG

Indium-111 Pentreotide

DRUG

Gallium-68 DOTATATE

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Marcelo F. Di Carli, MD, FACC

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546388 on ClinicalTrials.gov